Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Elevation Oncology Inc (ELEV)

Elevation Oncology Inc (ELEV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 32,466
  • Shares Outstanding, K 54,638
  • Annual Sales, $ 0 K
  • Annual Income, $ -45,700 K
  • 60-Month Beta 1.26
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.41
Trade ELEV with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.85
  • Most Recent Earnings $-0.18 on 08/06/24
  • Next Earnings Date 11/07/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 61.71%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.20
  • Number of Estimates 4
  • High Estimate -0.20
  • Low Estimate -0.21
  • Prior Year -0.25
  • Growth Rate Est. (year over year) +20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5942 unch
on 09/18/24
0.8358 -28.91%
on 08/20/24
-0.1165 (-16.39%)
since 08/16/24
3-Month
0.5942 unch
on 09/18/24
3.2800 -81.88%
on 07/16/24
-2.1658 (-78.47%)
since 06/18/24
52-Week
0.3630 +63.69%
on 11/13/23
5.8299 -89.81%
on 04/03/24
-0.1302 (-17.97%)
since 09/18/23

Most Recent Stories

More News
5 Biotech Stocks Under $10 With Multibagger Potential

As the biotech industry continues to redefine the healthcare landscape, here are five penny biotech stocks poised for meteoric growth in this evolving industry.

ADCT : 3.10 (-0.64%)
$SPX : 5,618.26 (-0.29%)
RZLT : 4.87 (-2.40%)
TRVI : 3.41 (+2.40%)
ELEV : 0.5942 (-1.54%)
CRDL : 2.20 (+2.80%)
Up 825% So Far in 2024, Can This Penny Stock Go Any Higher?

Despite its outsized year-to-date gains, Wall Street expects this breakout penny stock to soar 55% higher, on average.

ELEV : 0.5942 (-1.54%)
$SPX : 5,618.26 (-0.29%)
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:AMGN),(NASDAQ:AMAM),(NASDAQ:ELEV),(NASDAQ:NKTX) EQNX::TICKER_END

ONCY : 0.9300 (-2.99%)
ONC.TO : 1.28 (-1.54%)
AMGN : 332.92 (+0.04%)
AMAM : 28.00 (+0.07%)
ELEV : 0.5942 (-1.54%)
NKTX : 5.27 (-2.23%)
Elevation Oncology to Present at the H.C. Wainwright 25th Annual Global Investment Conference

/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...

ELEV : 0.5942 (-1.54%)
Elevation Oncology Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating EO-3021

/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...

ELEV : 0.5942 (-1.54%)
Elevation Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Business Achievements

/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...

ELEV : 0.5942 (-1.54%)
Elevation Oncology Appoints Joseph Ferra as Chief Executive Officer and Promotes Tammy Furlong to Chief Financial Officer

/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...

ELEV : 0.5942 (-1.54%)
Elevation Oncology Announces Pricing of $50 Million Public Offering

/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...

ELEV : 0.5942 (-1.54%)
Elevation Oncology Announces Launch of Proposed Public Offering

/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...

ELEV : 0.5942 (-1.54%)
Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023

/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...

ELEV : 0.5942 (-1.54%)

Business Summary

Elevation Oncology Inc. is a clinical stage biopharmaceutical company. It focused on the development of precision medicines for patients with genomically defined cancers. Elevation Oncology Inc. is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 0.6320
2nd Resistance Point 0.6245
1st Resistance Point 0.6093
Last Price 0.5942
1st Support Level 0.5866
2nd Support Level 0.5791
3rd Support Level 0.5639

See More

52-Week High 5.8299
Fibonacci 61.8% 3.7415
Fibonacci 50% 3.0964
Fibonacci 38.2% 2.4514
Last Price 0.5942
52-Week Low 0.3630

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar